Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 51-61

  Schwandt, Anita ^a   Wood, Laura S ^a   Rini, Brian ^a,b   Dreicer, Robert ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Renal cell carcinoma; Side effects; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ATANZANAVIR; AVEENO; BAG BALM; BIAFINE; BIOTIN; BLISTEX; BURTS BEES; CARBAMAZEPINE; CARMEX; CARMOL; CLARITHROMYCIN; CRON HUSKERS LOTION; CYTOCHROME P450 3A4 INHIBITOR; DEXAMETHASONE; DILTIAZEM; GELCLAIR; GOLD BOND; GRAPEFRUIT EXTRACT; ITRACONAZOLE; KERALAC; KERASAL; KETOCONAZOLE; LANOLIN ALCOHOL; LIDAMANTLE; LIDAMANTLE HC; MIRACLE FOOT REPAIR; NEFAZODONE; NELFINAVIR; NEUROLEPTIC AGENT; OXIDOREDUCTASE INHIBITOR; PHENOBARBITAL; PHENYTOIN; RGENECARE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RINCINOL PRN; RITONAVIR; SAQUINAVIR; SMOOTH; SORAFENIB; SUNITINIB; TELITHROMYCIN; THYROID HORMONE; TOOTHPASTE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VORICONAZOLE; XENADERM; XIPAMIDE; ZIMS CRACK CREME;

ACUTE CORONARY SYNDROME; ADVERSE DRUG REACTION; ANEMIA; ANOREXIA; BLOATING; BLOOD PRESSURE MONITORING; BLOOD TOXICITY; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN TOXICITY; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EVALUATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIARRHEA; DIET THERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; ELECTROCARDIOGRAM; FATIGUE; FLATULENCE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; HYPOTHYROIDISM; INTRACRANIAL HYPERTENSION; KIDNEY CARCINOMA; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIFESTYLE MODIFICATION; MALNUTRITION; MOUTH HYGIENE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROSURGERY; NEUTROPENIA; NUTRITION; ORAL REHYDRATION THERAPY; QT PROLONGATION; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN DISEASE; SOCIAL SUPPORT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

EID: 77953419143     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin Oncol. 2006;33(5):527-533. (Pubitemid 44511980)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865-875.
4. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005;23(3):202-212. (Pubitemid 41136043)
5. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: The multiethnic cohort. Am J Epidemiol. 2007;166(8):932-940. (Pubitemid 47511687)
6. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: Molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens. 2002;11(1):37-42. (Pubitemid 34053336)
7. Latif F, Tory K, Gnarra J, et al. Identification of the von hippel-lindau disease tumor suppressor gene. Science. 1993;260(5112):1317-1320. (Pubitemid 23231974)
8. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23(5):1028-1043. (Pubitemid 46202321)
9. Chow LQ, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884-896.
10. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337. (Pubitemid 36109749)
11. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25-35. (Pubitemid 46630490)
12. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16-24. (Pubitemid 46630489)
13. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516-2524. (Pubitemid 43854967)
14. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. (Pubitemid 46089672)
15. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts). 2008;26(15 suppl):5024.
16. Porta C, Szczylik C, Bracarda S, et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts). 2008;26(15 suppl):5114.
17. van der Veldt AA, Boven E, Helgason HH, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99(2):259-265.
18. Houk BE, Bello CL, Michaelson MD, et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/ pharmacodynamic (PKPD) approach. ASCO Meeting Abstracts. 2007;25(18 suppl):5027.
19. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):160S-198S. (Pubitemid 351892962)
20. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99(1):81-83.
21. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: A prospective evaluation. Br J Cancer. 2008;99(3):448-454.
22. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17(4):351-355. (Pubitemid 46776140)
23. Sica DA. Angiogenesis inhibitors and hypertension: An emerging issue. J Clin Oncol. 2006;24(9):1329-1331.
24. Dallabrida SM, Ismail N, Pravda EA, et al. Abstract 1505: Sunitinib-induced cardiotoxicity is mediated in part via direct effects on cardiac myocytes and smooth muscle cells. Circulation. 2007;116(16 MeetingAbstracts):II 311.
25. Kido M, Du L, Sullivan CC, et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol. 2005;46(11):2116-2124. (Pubitemid 41713601)
26. Parisi Q, Biondi-Zoccai GG, Abbate A, et al. Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. Int J Cardiol. 2005;99(2):337-339. (Pubitemid 40320813)
27. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011-2019. (Pubitemid 350236338)
28. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500-2508.
29. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204-5212.
30. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557-566.
31. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering pandora's vase: The growing problem of new toxicities from novel anticancer agents. the case of sorafenib and sunitinib. Clin Exp Med. 2007;7(4):127-134.
32. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491-500. (Pubitemid 40903630)
33. Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol. 2008;53(2):376-381. (Pubitemid 350296582)
34. Unnithan JS, Choueiri T, Garcia J, et al. Safety of VEGF-targeted tyrosine kinase inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases. J Clin Oncol (Meeting Abstracts). 2007;25(18 suppl):5047.
35. Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007;25(23):3559. (Pubitemid 47310905)
36. Nicholaou T, Wong R, Davis ID. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet. 2007;369(9577):1923- 1924. (Pubitemid 46874569)
37. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007;178(5):1883-1887. (Pubitemid 47538608)
38. Rini BI, Choueiri TK, Elson P, et al. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer. 2008;113(6):1309-1314.
39. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics. 2003;13(5):247-252.
40. Common Terminology Criteria for Adverse Events (CTCAE version 3.0). National Institutes of Health. 2003. Accessed on the Cancer Therapy Evaluation Program (CTEP). Available at http://ctep.info.nih.gov.
41. Sunitinib (Sutent® ) [package insert]. 2007. New York, NY: Pfizer Labs, Division of Pfizer Pharmaceuticals; 2007.
42. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19(9):1613-1618.